Lukes D J, Herlenius G, Rizell M, Mjörnstedt L, Bäcman L, Olausson M, Friman S
Department of Surgery and Transplantation, Sahlgrenska University Hospital, Göteborg, Sweden.
Transplant Proc. 2006 Oct;38(8):2671-2. doi: 10.1016/j.transproceed.2006.07.029.
Liver transplantation (OLT) is an established treatment with excellent early outcome. However, the long-term results are hampered by side effects of immunosuppression, cardiovascular morbidity, recurrent disease, and chronic rejection. We analyzed causes of late death (>/=2 years post-OLT) in 679 consecutive primary recipients in our institution.
A total of 679 primary OLT recipients including those retransplanted within 3 months between January 1985 and August 2005 were identified; 460 (67.7%) patients survived >/=2 years. The indications were cholestatic disease (35.1%), postviral (11.4%), alcoholic (12.9%), fulminant hepatic failure (7.0%), cryptogenic (3.1%), autoimmune hepatitis (4.8%), malignancy (7.7%), and others (18.0%). Sixty three patients (9.3%) died >/=2 years post-OLT. For 51 patients, sufficient records were present to establish the cause of death.
Four hundred sixty (67.7%) patients survived >/=2 years. Their median age was 58 years with, 43.7% older than 60 and 11.1% older than 70 years. Sixty three patients (9.3%) died at a median time of 69 +/- 4.8 months post-primary OLT; 49.1% died of malignancy and 13.7% of vascular complications and infectious complications respectively.
Late mortality in our material is mainly due to malignant disease. Compared to other published reports on late mortality, the proportion of malignancy, especially recurrent, as cause of late death is higher. This might reflect a more generous approach toward accepting older patients and a higher proportion of patients with various malignant diseases accepted for OLT.
肝移植(OLT)是一种已确立的治疗方法,早期疗效极佳。然而,免疫抑制的副作用、心血管疾病发病率、疾病复发和慢性排斥反应阻碍了其长期效果。我们分析了我院679例连续初次接受肝移植患者的晚期死亡(OLT术后≥2年)原因。
确定了1985年1月至2005年8月期间共679例初次OLT受者,包括那些在3个月内再次移植的患者;460例(67.7%)患者存活≥2年。适应证包括胆汁淤积性疾病(35.1%)、病毒感染后(11.4%)、酒精性(12.9%)、暴发性肝衰竭(7.0%)、隐源性(3.1%)、自身免疫性肝炎(4.8%)、恶性肿瘤(7.7%)及其他(18.0%)。63例(9.3%)患者在OLT术后≥2年死亡。对于51例患者,有足够的记录来确定死亡原因。
460例(67.7%)患者存活≥2年。他们的中位年龄为58岁,43.7%的患者年龄大于60岁,11.1%的患者年龄大于70岁。63例(9.3%)患者在初次OLT术后中位时间69±4.8个月死亡;分别有49.1%的患者死于恶性肿瘤,13.7%的患者死于血管并发症和感染性并发症。
我们资料中的晚期死亡率主要归因于恶性疾病。与其他关于晚期死亡率的已发表报告相比,作为晚期死亡原因的恶性肿瘤,尤其是复发肿瘤的比例更高。这可能反映出在接受老年患者方面采取了更宽松的方法,以及接受OLT的各种恶性疾病患者比例更高。